Miscellaneous cell wall synthesis inhibitors

33,800views

Miscellaneous cell wall synthesis inhibitors

PED STEP2

PED STEP2

Eating disorders: Pathology review
Psychiatric emergencies: Pathology review
Attributable risk (AR)
Bias in interpreting results of clinical studies
Bias in performing clinical studies
Clinical trials
Confounding
DALY and QALY
Direct standardization
Disease causality
Incidence and prevalence
Indirect standardization
Interaction
Mortality rates and case-fatality
Odds ratio
Positive and negative predictive value
Prevention
Relative and absolute risk
Selection bias
Sensitivity and specificity
Study designs
Test precision and accuracy
Acyanotic congenital heart defects: Pathology review
Adrenal masses: Pathology review
Bacterial and viral skin infections: Pathology review
Bone tumors: Pathology review
Coagulation disorders: Pathology review
Congenital neurological disorders: Pathology review
Cyanotic congenital heart defects: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Headaches: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Leukemias: Pathology review
Lymphomas: Pathology review
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Pediatric brain tumors: Pathology review
Pediatric musculoskeletal disorders: Pathology review
Platelet disorders: Pathology review
Renal and urinary tract masses: Pathology review
Seizures: Pathology review
Viral exanthems of childhood: Pathology review
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Drug-receptor interactions
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Cystic fibrosis: Pathology review
Diabetes mellitus: Pathology review
HIV and AIDS: Pathology review
Obstructive lung diseases: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Antidiuretic hormone
Body fluid compartments
Movement of water between body compartments
Sodium homeostasis
Acid-base disturbances: Pathology review
Diabetes insipidus and SIADH: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Growth hormone and somatostatin
Childhood and early-onset psychological disorders: Pathology review
Breastfeeding
Central nervous system infections: Pathology review
Congenital TORCH infections: Pathology review
Jaundice: Pathology review
Respiratory distress syndrome: Pathology review
Ectoderm
Endoderm
Human development days 1-4
Human development days 4-7
Human development week 2
Human development week 3
Mesoderm
Cell cycle
DNA damage and repair
DNA mutations
DNA replication
DNA structure
Epigenetics
Gene regulation
Mitosis and meiosis
Nuclear structure
Transcription of DNA
Translation of mRNA
Hardy-Weinberg equilibrium
Independent assortment of genes and linkage
Inheritance patterns
Mendelian genetics and punnett squares
Autosomal trisomies: Pathology review
Disorders of sex chromosomes: Pathology review
Miscellaneous genetic disorders: Pathology review
Baroreceptors
Cardiac preload
Chemoreceptors
Renin-angiotensin-aldosterone system
Adrenal insufficiency: Pathology review
Congenital gastrointestinal disorders: Pathology review
Environmental and chemical toxicities: Pathology review
Gastrointestinal bleeding: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Medication overdoses and toxicities: Pathology review
Pneumonia: Pathology review
Shock: Pathology review
Supraventricular arrhythmias: Pathology review
Traumatic brain injury: Pathology review
Ventricular arrhythmias: Pathology review
Introduction to pharmacology
Androgens and antiandrogens
Estrogens and antiestrogens
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Antihistamines for allergies
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Glucocorticoids
Azoles
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Developmental milestones: Clinical
Disruptive, impulse-control and conduct disorders: Clinical
Eating disorders: Clinical
Elimination disorders: Clinical
Neurodevelopmental disorders: Clinical
Child abuse: Clinical
BRUE, ALTE, and SIDS: Clinical
Congenital heart defects: Clinical
Fever of unknown origin: Clinical
Kawasaki disease: Clinical
Pediatric bone and joint infections: Clinical
Pediatric constipation: Clinical
Pediatric ear, nose, and throat conditions: Clinical
Pediatric gastrointestinal bleeding: Clinical
Pediatric infectious rashes: Clinical
Pediatric lower airway conditions: Clinical
Pediatric ophthalmological conditions: Clinical
Pediatric orthopedic conditions: Clinical
Pediatric upper airway conditions: Clinical
Pediatric urological conditions: Clinical
Pediatric vomiting: Clinical
Adrenal masses and tumors: Clinical
Asthma: Clinical
Cystic fibrosis: Clinical
Diabetes mellitus: Clinical
Leukemia: Clinical
Lymphoma: Clinical
Pediatric allergies: Clinical
Pediatric bone tumors: Clinical
Seizures: Clinical
Sickle cell disease: Clinical
Chronic kidney disease: Clinical
Heart failure: Clinical
Hyperkalemia: Clinical
Hypernatremia: Clinical
Hypokalemia: Clinical
Hyponatremia: Clinical
Metabolic and respiratory acidosis: Clinical
Shock: Clinical
Mood disorders: Clinical
Congenital disorders: Clinical
Neonatal ICU conditions: Clinical
Neonatal jaundice: Clinical
Newborn management: Clinical
Perinatal infections: Clinical
Bleeding disorders: Clinical
Immunodeficiencies: Clinical
Brain tumors: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Toxidromes: Clinical
Vaccinations: Clinical

Transcript

Watch video only

Beta lactam antibiotics, such as penicillins and cephalosporins, have a beta-lactam ring in their structure, which gives them their name.

These medications inhibit cell wall synthesis in bacteria. Unfortunately for us, bacteria are becoming increasingly resilient to beta lactams, so we’ve come up non-beta lactam medications to inhibit cell wall synthesis.

So, our body is made out of eukaryotic cells.

Bacterias belong to a different type of cells, called the prokaryotes.

From the outside to inside, they have a slimy capsule made out of polysaccharides.

Then, there’s a cell wall in most prokaryotes.

A cell wall is a structural layer, which encapsulates bacteria, and offers structural support and protection, like a suit of armor. It also offers some filtering capabilities, as not everything can pass freely through it.

Finally, on the inside, there’s a pretty standard cell membrane.

Should something happen to this wall, say, if its synthesis mysteriously stopped, its owner’s life expectancy will turn to that of a snowflake in Sahara. And that’s exactly what we’re hoping to do.

Bacterial cell walls are made of a substance called peptidoglycan, or murein.

Peptidoglycan is a very strong, crystal lattice resembling three-dimensional structure, composed out of long using “strands” of amino polysaccharides, running in parallel.

These are made of made out segments of N-acetylglucosamine, or NAG, and N-acetylmuramic acid, or NAM, in an alternating pattern - so, NAG, NAM, NAG, NAM, and so on, like a pearl necklace.

These strands are also cross linked by short, four to five amino acids long, or tetrapeptide chains, protruding from NAM subunits.

Those pentapeptides reach out and link to pentapeptide chains from the neighboring strands, for structural stability, a sub-process known as transpeptidation.

All of this is made possible by enzymes called DD-transpeptidases, that are also better known as penicillin binding proteins, or PBPs.

These enzymes are highly specialized to grab and hold two pentapeptide ends and fuse them together, creating a stable link between the two polysaccharide strands, essentially creating peptidoglycan.

If you imagine the enzyme as a “lock”, then the pentapeptide chain would be a key, so it fits perfectly in, and allows the enzyme to do its work.

In essence, all beta lactam antibiotics, like the cephalosporins, somewhat resemble the tetrapeptide chains.

Inside the bacteria, PBP enzymes will mistakenly bind to the beta lactams antibiotic molecule instead of a tetrapeptide and stick inside the PBP forever, like chewing gum in a keyhole, permanently disabling it.

As more and more of PBPs get disabled, the crosslinking fails to occur, and the wall becomes weak and unstable.

If the affected bacteria attempts to divide, their cell wall will collapse, killing them in the process!

Now, some bacteria have developed resistance to beta lactam antibiotics.

The most notable is the notorious staphylococcus aureus, which evolved an enzyme called beta lactamases or penicillinases that breaks down the beta lactam ring within the antibiotic, rendering it ineffective.

In response, we started adding beta lactamase inhibitors, such as clavulanic acid, that would binding to beta lactamases and inactivate them, like the gum into the keyhole.

Another approach was to create newer kinds of beta lactam antibiotics like methicillin, which had a large side chain that wouldn’t “fit” into the keyhole of the beta lactamase.

They did work quite well, until some staphylococcus aureus developed PBP site mutations that changed the shape of the keyhole.

So even if beta lactamase enzymes can’t break down these antibiotics, they won’t fit into the PBP enzyme and thus won’t work.

We call these bacteria methicillin resistant staphylococcus aureus, or MRSA.

This poses a huge problem, as it makes MRSA virtually untreatable by beta lactam antibiotics.

Now, to overcome these resistances, we have found ways to inhibit cell wall synthesis at multiple stages.

We want to make a simple and fun mnemonic that’ll help you efficiently memorize the medications that work on each of these stages. So, first we can use bacteria carrying wheelbarrows for the transport proteins that move NAM and NAG across the cell membrane.

Next, are the bacterial security guards which represents the beta lactamase enzymes. They are protecting the bacterial masons which are the PBPs that build the cell wall. Finally we have the wall itself, which is under construction.

Our first class of medication is the bactoprenol inhibitors, such as bacitracin.

It works by blocking bactoprenol phosphate, which is the transmembrane transporter embedded within the bacterial cell membrane.

It lets NAM and NAG molecules cross from inside the cell membrane to the outside, where they’re needed for the synthesis of peptidoglycan.

Once the transport protein is inhibited, new peptidoglycan can no longer be made.

Bacitracin has a very narrow spectrum and only works against a few gram positive bacteria like Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pyogenes - and even then, it only works topically - meaning, it is used to treat skin and eye infections by rubbing it onto the affected area.

They are never to be applied IV or IM, as they are highly nephrotoxic, and can lead to renal failure if used for systemic infections.

Back to the mnemonic. For this class of medication, we are attacking bacterial membrane transport proteins represented by the wheelbarrows. Let’s have a basilisk, representing bacitracin attack them. These bacteria are purple since bacitracin works on common gram positive bacteria that stains purple. Let’s have it shed its skin because this medication is for topical use only for treating certain skin infections.

Next, let’s look at how we can overcome the beta lactamase problem. One way is to shut them down with beta lactamase inhibitors.

Members of this group include clavulanic acid, tazobactam and sulbactam.

Key Takeaways

The inhibition of bacteria's cell wall synthesis is a common and successful strategy for treating a broad range of bacterial infection. The major cell wall synthesis inhibitors currently in use are the beta-lactams (e.g., penicillin and cephalosporins), which block the formation of the peptidoglycan layer, and glycopeptides (vancomycin and teicoplanin), which disrupt assembly of the peptidoglycan precursor lipid II.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Penicillin-Binding Proteins of Gram-Negative Bacteria" Clinical Infectious Diseases (1988)
  5. "Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management" The American Journal of Medicine (1993)
  6. "A systematic review and meta-analysis on the use of prophylactic topical antibiotics for the prevention of uncomplicated wound infections" Infection and Drug Resistance (2018)
  7. "UREIDOPENICILLINS AND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS" Infectious Disease Clinics of North America (2000)
  8. "Carbapenems" Medical Clinics of North America (1995)
  9. "CEPHALOSPORINS, CARBAPENEMS, AND MONOBACTAMS" Infectious Disease Clinics of North America (2000)
  10. "Therapeutic Monitoring of Vancomycin in Adults" Pharmacotherapy (2009)